Format

Send to

Choose Destination
Br J Cancer. 2004 Oct 18;91(8):1415-9.

Targeting the p53-MDM2 interaction to treat cancer.

Author information

1
Pharma Research, Roche Diagnostics GmbH, Penzberg D-82372, Germany.

Abstract

The tumour suppressor p53 is a transcription factor with powerful antitumour activity that is controlled by its negative regulator MDM2 (mouse double minute 2, also termed HDM2 in humans) through a feedback mechanism. MDM2, which is overproduced in many tumours, binds p53 and inhibits its function by modulating its transcriptional activity and stability. Activation of p53 in tumour cells by inhibiting its physical interaction with MDM2 has been in the focus of cancer drug discovery. However, development of nonpeptidic MDM2 antagonists turned out to be challenging. Recently, the first potent and selective small-molecule antagonists of MDM2, the Nutlins, have been identified. Studies with Nutlins provided in vitro and in vivo proof-of-principle for targeting p53-MDM2 interaction for cancer therapy.

PMID:
15452548
PMCID:
PMC2409943
DOI:
10.1038/sj.bjc.6602164
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center